Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
34 Leser
Artikel bewerten:
(0)

Denver's HealthONE And Sarah Cannon Launch Cancer Care Collaborative

DENVER, Jan. 30, 2014 /PRNewswire/ --The HealthONE family of hospitals and Sarah Cannon have formally launched an integrated cancer initiative at The Medical Center of Aurora, North Suburban Medical Center, Presbyterian/St. Luke's Medical Center, Rose Medical Center, Sky Ridge Medical Center and Swedish Medical Center. Through this collaboration, HealthONE is enhancing its cancer programs by joining forces with the Sarah Cannon Cancer Network of Excellence to fulfill the mission of advancing science and transforming care.

"HealthONE's hospitals have long been recognized for their expertise in cancer care, and by partnering with Sarah Cannon, we continue to build upon our strong reputation by delivering expanded treatment and research options for our patients," said Sylvia Young, President and CEO, HealthONE. "Our combined efforts ensure that patients across the region have access to the most innovative and personalized care, including an individualized patient navigation program to support and educate them throughout the cancer treatment journey."

Beginning in 2013, the Sarah Cannon at HealthONE Cancer Network of Excellence enhanced their clinical programs by increasing services for treatments, physician leadership, and patient access to care and clinical trials. The Colorado Blood Cancer Institute (CBCI) is enrolling patients in Sarah Cannon clinical trials, providing access to breakthrough therapies. Dr. Jeffrey Matous with CBCI stated, "Teaming with Sarah Cannon provides HealthONE patients and physicians the earliest possible access to clinical trials of promising drugs, which can be life-changing for patients who are battling all types of cancer."

Additionally, Sarah Cannon at HealthONE physician workgroups have guided development of comprehensive breast and lung cancer programs, further strengthening the breadth of cancer expertise here in Denver. By the end of 2014, HealthONE and Sarah Cannon will fully integrate their cancer services to positively impact care from screening and diagnosis through treatment to survivorship.

"The battle against cancer requires a team of committed experts," said Dee Anna Smith, CEO, Sarah Cannon. "It takes doctors, researchers, nurses, support staff, caregivers and patients banding together to move the fight forward - and through our integrated approach with HealthONE, we are providing such support and expert care to patients throughout Denver and the surrounding region."

This Sarah Cannon and HealthONE approach to fighting cancer will be highlighted in an integrated awareness campaign, Together, that can be seen throughout the Denver area in print, television, radio, and online communication efforts, and by visiting FightingCancerTogether.com.

HealthONE

HealthONE is the largest healthcare system in the metro Denver area with more than 10,000 employees. As part of the HealthONE family, The Medical Center of Aurora, North Suburban Medical Center, Presbyterian/St. Luke's Medical Center, Rocky Mountain Hospital for Children, Rose Medical Center, Sky Ridge Medical Center, Swedish Medical Center, and Spalding Rehabilitation Hospital work together to provide a higher level of care. In addition, our family of services includes four hospital outpatient provider emergency departments and numerous ambulatory surgery centers, occupational medicine & rehabilitation clinics, physician practices, radiation oncology centers, and AIRLIFE-DENVER, which provides critical care air and ground transportation across a 10-state region.

To learn more about the HealthONE family, go to HealthONECares.com.

Sarah Cannon Cancer Network of Excellence

Sarah Cannon is the cancer service line of HealthONE's parent company, the Hospital Corporation of America (HCA), which advances science and transforms care in communities across the United States and United Kingdom. While the care service line was launched in 2011, Sarah Cannon has had a rich history in clinical research beginning in 1993 when its research investigators brought clinical trials into the community setting. The global network's cancer care reach includes individualized patient navigation provided by oncology-trained nurse navigators, experience with more than 110 first-in-man clinical trials conducted, more than 800 stem cell transplants performed annually throughout the Sarah Cannon Blood Cancer Network and the first community-based molecular profiling program. Through its programs, Sarah Cannon Cancer Network of Excellence is providing state-of-the- art cancer care close to home for hundreds of thousands of patients, a number unmatched by any single cancer center.

To learn more about Sarah Cannon, go to sarahcannon.com.

SOURCE HealthONE

© 2014 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.